NICE says it can approve BioMarin's ultra-rare drug treatment Vimizim, but has proposed real-world data collection and a price cap to overcome doubts about the drug's value, reports Andrew McConaghie.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, BMRN should be on investors' short list. Should You Invest in BioMarin Pharmaceutical Inc. (BMRN)? Before you invest in BioMarin ...
So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks. San Rafael, CA-based BioMarin ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...
Zacks Research cut their Q2 2026 earnings estimates for shares of BioMarin Pharmaceutical in a research report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now expects that the ...
Zacks Investment Research on MSN6d
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have added about 4.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
With a solid Zacks Rank and top-tier Value and VGM Style Scores, BMRN should be on investors' short list. Should You Invest in BioMarin Pharmaceutical Inc. (BMRN)? Before you invest in BioMarin ...
The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks. San Rafael, CA-based BioMarin Pharmaceutical Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback